Post-Translational Peptide Splicing and T Cell Responses

Trends in Immunology

Volumn 38, Issue 12, 2017, Pages 904-915

  Mishto, Michele ^a,b   Liepe, Juliane ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; INSULIN PEPTIDE; PEPTIDE; PROTEASOME; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN; HLA ANTIGEN CLASS 1;

AUTOIMMUNITY; CD8+ T LYMPHOCYTE; HUMAN; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PROCESSING; PROTEIN SPLICING; REVIEW; ANIMAL; ANTIGEN PRESENTATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; PROTEIN DEGRADATION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYMPHOCYTE ACTIVATION; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS;

EID: 85027695492     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.07.011     Document Type: Review

References (87)

1. Groettrup, M., et al. Proteasomes in immune cells: more than peptide producers?. Nat. Rev. Immunol. 10 (2010), 73–78.
2. Xing, Y., et al. Thymoproteasome subunit-beta5T generates peptide-MHC complexes specialized for positive selection. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 6979–6984.
3. + T cell development by thymus-specific proteasomes. Science 316 (2007), 1349–1353.
4. + T cells. Nat. Immunol. 17 (2016), 938–945.
5. + T cells. Immunity 32 (2010), 29–40.
6. Vigneron, N., et al. An antigenic peptide produced by peptide splicing in the proteasome. Science 304 (2004), 587–590.
7. Hanada, K., et al. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 427 (2004), 252–256.
8. Dalet, A., et al. Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5. J. Immunol. 184 (2010), 3016–3024.
9. Warren, E.H., et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science 313 (2006), 1444–1447.
10. Michaux, A., et al. A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming. J. Immunol. 192 (2014), 1962–1971.
11. Dalet, A., et al. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), E323–E331.
12. Textoris-Taube, K., et al. The T210 M substitution in the HLA-a*02:01 gp100 epitope strongly affects overall proteasomal cleavage site usage and antigen processing. J. Biol. Chem. 290 (2015), 30417–30428.
13. Mishto, M., et al. Driving forces of proteasome-catalyzed peptide splicing in yeast and humans. Mol. Cell. Proteomics 11 (2012), 1008–1023.
14. Liepe, J., et al. The 20S proteasome splicing activity discovered by SpliceMet. PLoS Comput. Biol., 6, 2010, e1000830.
15. Berkers, C.R., et al. Definition of proteasomal peptide splicing rules for high-efficiency spliced peptide presentation by MHC class I molecules. J. Immunol. 195 (2015), 4085–4095.
16. Ebstein, F., et al. Proteasomes generate spliced epitopes by two different mechanisms and as efficiently as non-spliced epitopes. Sci Rep., 6, 2016, 24032.
17. Liepe, J., et al. A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science 354 (2016), 354–358.
18. Wiles, T.A., et al. An insulin–IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J. Autoimmun. 78 (2017), 11–18.
19. Delong, T., et al. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science 351 (2016), 711–714.
20. Babon, J.A., et al. Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes. Nat. Med. 22 (2016), 1482–1487.
21. Borissenko, L., Groll, M., Diversity of proteasomal missions: fine tuning of the immune response. Biol. Chem. 388 (2007), 947–955.
22. Berkers, C.R., et al. Peptide splicing in the proteasome creates a novel type of antigen with an isopeptide linkage. J. Immunol. 195 (2015), 4075–4084.
23. Dalet, A., et al. Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome. Eur. J. Immunol. 41 (2011), 39–46.
24. + T cells of Listeria monocytogenes-infected mice recognize both linear and spliced proteasome products. Eur. J. Immunol. 46 (2016), 1109–1118.
25. Liepe, J., et al. Quantitative time-resolved analysis reveals intricate, differential regulation of standard- and immuno-proteasomes. Elife, 4, 2015, e07545.
26. Gubin, M.M., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
27. Berlin, C., et al. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy. Leukemia 29 (2015), 647–659.
28. Bassani-Sternberg, M., et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun., 7, 2016, 13404.
29. Mishto, M., et al. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur. J. Immunol. 44 (2014), 3508–3521.
30. Kincaid, E.Z., et al. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat. Immunol. 13 (2011), 129–135.
31. Deol, P., et al. Rates of processing determine the immunogenicity of immunoproteasome-generated epitopes. J. Immunol. 178 (2007), 7557–7562.
32. + T cell responses. J. Immunol. 191 (2013), 52–59.
33. Bassani-Sternberg, M., et al. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol. Cell. Proteomics 14 (2015), 658–673.
34. +-IMAC and label-free quantitation enables in-depth monitoring of phosphorylation dynamics with high reproducibility and temporal resolution. Mol. Cell. Proteomics 13 (2014), 2426–2434.
35. Cox, J., et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol. Cell. Proteomics 13 (2014), 2513–2526.
36. Caron, E., et al. An open-source computational and data resource to analyze digital maps of immunopeptidomes. Elife, 4, 2015, e07661.
37. Lossl, P., et al. The diverse and expanding role of mass spectrometry in structural and molecular biology. EMBO J. 35 (2016), 2634–2657.
38. Platteel, A.C.M., et al. Strategies to enhance immunogenicity of cDNA vaccine encoded antigens by modulation of antigen processing. Vaccine 34 (2016), 5132–5140.
39. Tenzer, S., et al. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat. Immunol. 10 (2009), 636–646.
40. Guillaume, B., et al. Analysis of the processing of seven human tumor antigens by intermediate proteasomes. J. Immunol. 189 (2012), 3538–3547.
41. Chapiro, J., et al. Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176 (2006), 1053–1061.
42. Belogurov, A. Jr, et al. Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity. FASEB J. 29 (2015), 1901–1913.
43. Schwarz, K., et al. Overexpression of the proteasome subunits LMP2, LMP7, and MECL-1, but not PA28 alpha/beta, enhances the presentation of an immunodominant lymphocytic choriomeningitis virus T cell epitope. J. Immunol. 165 (2000), 768–778.
44. Robbins, P.F., et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 54 (1994), 3124–3126.
45. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc. Natl. Acad. Sci. U. S. A. 96 (1999), 8639–8644.
46. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
47. Blankenstein, T., et al. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr. Opin. Immunol. 33 (2015), 112–119.
48. Coulie, P.G., et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 135–146.
49. Tran, E., et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375 (2016), 2255–2262.
50. Screaton, G., et al. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15 (2015), 745–759.
51. Haynes, B.F., New approaches to HIV vaccine development. Curr. Opin. Immunol. 35 (2015), 39–47.
52. Ewer, K.J., et al. Viral vectors as vaccine platforms: from immunogenicity to impact. Curr. Opin. Immunol. 41 (2016), 47–54.
53. + T cells in bacterial infection. Cell Rep. 20 (2017), 1242–1253, 10.1016/j.celrep.2017.07.026 PMID: 28768206.
54. Calis, J.J., et al. Degenerate T-cell recognition of peptides on MHC molecules creates large holes in the T-cell repertoire. PLoS Comput. Biol., 8, 2012, e1002412.
55. Handel, A.E., et al. Environmental factors and their timing in adult-onset multiple sclerosis. Nat. Rev. Neurol. 6 (2010), 156–166.
56. + T cells in type 1 diabetes. Nat. Immunol. 13 (2012), 283–289.
57. Unger, W.W., et al. Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J. Autoimmun. 37 (2011), 151–159.
58. Skowera, A., et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118 (2008), 3390–3402.
59. Handel, A.E., et al. Type 1 diabetes mellitus and multiple sclerosis: common etiological features. Nat. Rev. Endocrinol. 5 (2009), 655–664.
60. Berkers, C.R., et al. Transpeptidation and reverse proteolysis and their consequences for immunity. Int. J. Biochem. Cell. Biol. 41 (2009), 66–71.
61. Manoury, B., et al. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature, 396, 1998 695–609.
62. Pearson, H., et al. MHC class I-associated peptides derive from selective regions of the human genome. J. Clin. Invest. 126 (2016), 4690–4701.
63. McShane, E., et al. Kinetic analysis of protein stability reveals age-dependent degradation. Cell 167 (2016), 803–815.
64. Bourdetsky, D., et al. The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E1591–E1599.
65. Boisvert, F.M., et al. A quantitative spatial proteomics analysis of proteome turnover in human cells. Mol. Cell. Proteomics, 11, 2012 M111 011429.
66. Laumont, C.M., et al. Global proteogenomic analysis of human MHC class I-associated peptides derived from non-canonical reading frames. Nat Commun., 7, 2016, 10238.
67. Kracht, M.J., et al. Autoimmunity against a defective ribosomal insulin gene product in type 1 diabetes. Nat. Med. 23 (2017), 501–507.
68. Apcher, S., et al. Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 17951–17956.
69. Jia, Y., et al. Intergenically spliced chimeric RNAs in cancer. Trends Cancer 2 (2016), 475–484.
70. Xu, M.M., et al. The role of adaptive immunity in the efficacy of targeted cancer therapies. Trends Immunol. 37 (2016), 141–153.
71. Prior, I.A., et al. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72 (2012), 2457–2467.
72. Granados, D.P., et al. The nature of self for T cells – a systems-level perspective. Curr. Opin. Immunol. 34 (2015), 1–8.
73. Rock, K.L., et al. Re-examining class-I presentation and the DRiP hypothesis. Trends Immunol. 35 (2014), 144–152.
74. Anton, L.C., Yewdell, J.W., Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J. Leukoc. Biol. 95 (2014), 551–562.
75. Weinzierl, A.O., et al. Features of TAP-independent MHC class I ligands revealed by quantitative mass spectrometry. Eur. J. Immunol. 38 (2008), 1503–1510.
76. Wei, M.L., Cresswell, P., HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 356 (1992), 443–446.
77. Rock, K.L., et al. Present yourself! By MHC class I and MHC class II molecules. Trends Immunol. 37 (2016), 724–737.
78. Ben-Nissan, G., Sharon, M., Regulating the 20S proteasome ubiquitin-independent degradation pathway. Biomolecules 4 (2014), 862–884.
79. Ruschak, A.M., Kay, L.E., Proteasome allostery as a population shift between interchanging conformers. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E3454–3462.
80. Dick, T.P., et al. Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell 86 (1996), 253–262.
81. Vigneron, N., Van den Eynde, B.J., Proteasome subtypes and regulators in the processing of antigenic peptides presented by class I molecules of the major histocompatibility complex. Biomolecules 4 (2014), 994–1025.
82. Emmerich, N.P., et al. The human 26 S and 20 S proteasomes generate overlapping but different sets of peptide fragments from a model protein substrate. J. Biol. Chem. 275 (2000), 21140–21148.
83. Arciniega, M., et al. Differential global structural changes in the core particle of yeast and mouse proteasome induced by ligand binding. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 9479–9484.
84. Guillaume, B., et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 18599–18604.
85. Toes, R.E., et al. Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194 (2001), 1–12.
86. + T cells. Nat. Commun., 6, 2015, 7484.
87. Ebstein, F., et al. Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol. Life Sci. 69 (2012), 2543–2558.